Document:

Exhibit

            

  Exhibit 10.03

July 31, 2019

Martin Cole

Dear Martin:
On behalf of Cloudera, Inc. (the “Company”), this letter agreement (the “Agreement”) sets forth the terms and conditions of your appointment as Interim Chief Executive Officer of the Company.
		
	1.
	Position.  Effective as of August 1, 2019 or such earlier time as the Company’s current Chief Executive Officer may terminate service in such capacity (the “Start Date”), you will be appointed as the Company’s Interim Chief Executive Officer (“Interim CEO”) reporting to the Company’s Board of Directors (the “Board”).  You will have all of the duties, responsibilities and authority commensurate with the position of Chief Executive Officer, including those set forth in the Company’s Bylaws with respect to the Company’s Chief Executive Officer.

You will be expected to devote your full working time and attention to the business of the Company, and you will not render services to any other business without the prior approval of the Board, other than continuing service on the other corporate boards of directors on which you currently serve on the date hereof, and continuing service as an advisor to another for‐profit company for which you serve on the date hereof.  Notwithstanding the foregoing, you may manage personal investments, participate in civic, charitable, professional and academic activities (including serving on boards and committees), and, subject to prior approval by the Board, serve on the board of directors (and any committees) and/or as an advisor of other for‐profit companies, provided that such activities do not at the time the activity or activities commence or thereafter create an actual or potential business or fiduciary conflict of interest.  
During the Interim CEO Service Period (as defined below), you will continue as a member of the Board and we anticipate you will continue as a member of the Board following the Interim CEO Service Period (you were nominated by the Board for re‐election to the Board as Class II Director at the Company’s 2019 Annual Meeting) subject to your election by stockholders at such Annual Meeting.
		
	2.
	Term.  Subject to the terms of this Agreement, this Agreement will remain in effect for a period commencing on the Transition Start Date (as defined below) and ending on the appointment and commencement of service of a permanent Chief Executive Officer, or until such later end of a transition period that may be requested in writing by such permanent Chief Executive Officer (not to exceed sixty days following the commencement of service of such permanent Chief Executive 

Officer), unless earlier terminated by you or by a vote of the majority of independent directors of the Board (the “Interim CEO Service Period”).
		
	3.
	Cash Compensation.  

		
	a.
	Monthly Stipend.  Commencing July 1, 2019 (inclusive of your transition period to begin the role of Interim CEO) (the “Transition Start Date”) and during the Interim CEO Service Period you will receive a monthly stipend of forty thousand dollars ($40,000) per month or partial month (the “Stipend”) in accordance with the Company’s normal payroll practices.  Your Stipend will be reduced by the allocable portion of any cash director fees payable to you as a non‐employee director during the Interim CEO Service Period.

		
	b.
	Expenses and Reimbursement under Cloudera Policies.  The Company shall pay or reimburse you for all reasonable business expenses, other than any air travel/hotel/rental apartment or other commute‐related expenses for travel from your home in Florida to Palo Alto, California, incurred by you during the Interim CEO Service Period that are submitted in accordance with the Company’s expense reimbursement policies and procedures.

		
	4.
	Benefits & Vacation.  You will be entitled to participate in all employee retirement, welfare, insurance, benefit and vacation programs of the Company as are in effect from time to time and in which other senior executives of the Company are eligible to participate, on the same terms as such other senior executives.  Notwithstanding the foregoing, you will not participate in the Company’s Severance and Change in Control Plan.

		
	5.
	Equity Awards.  Subject to this Section 5, you will be granted a Time‐Based RSU as follows:

		
	a.
	Time‐Based RSU.  As soon as reasonably practicable but not later than the Start Date (the “Grant Date”), the Company will grant you a restricted stock unit to acquire such number of 577,035 shares of the Company’s common stock (the “Time‐Based RSU”) under the Company’s 2017 Equity Incentive Plan (the “Equity Plan”).  The Time‐Based RSU will vest quarterly (each a “Quarterly Vesting Period”) on the last day of each of the full three (3) month periods following your Transition Start Date (the “Quarterly Vesting Date”) at the rate of 37.50% for the first Quarterly Vesting Period, 31.50% for the second Quarterly Vesting Period and 15.50% for each of the third and fourth Quarterly Vesting Periods.  Notwithstanding the foregoing (i) vesting will be subject to your continued service as Interim Chief Executive Officer of the Company on each of the respective Quarterly Vesting Dates, and in the case of the Quarterly Vesting Period in which your service terminates, for at least one day during such Quarterly Vesting Period (in which event you will be credited for service of such full Quarterly Vesting Period), and will be subject to the terms and conditions of the written agreement governing the grant, the Equity Plan and this Agreement, provided that you shall vest with respect to the full amount of the first Quarterly Vesting Period, irrespective of the length of your service as Interim CEO, and (ii) at such time as the Interim CEO Service Period terminates for any reason, all further vesting shall cease at the end of the Quarterly 

2
        

Vesting Period in which you terminate, and any unvested Time‐Based RSUs will be cancelled; provided that if termination is for Cause, vesting shall terminate immediately.
		
	b.
	Treatment of Time‐Based RSU upon Change in Control.  Effective as of immediately prior to a Change in Control (as defined below) occurring during the Interim CEO Service Period, the vesting of any unvested Time‐Based RSU will accelerate in full provided that you (i) will execute a general release (in a form prescribed by the Company and provided to other executives similarly situated) (“General Release”) of all known and unknown claims that you may then have against the Company or persons affiliated with the Company and such release has become effective and (ii) have agreed not to prosecute any legal action or other proceeding based upon any of such claims. 

		
	6.
	Definitions.  As used in this Agreement, the following terms have the following meanings:

		
	a.
	Cause.  “Cause” means any or all of the following: (i) your deliberate and repeated failure to perform your duties and/or responsibilities, as assigned or delegated by the Company (ii) your conviction of a felony or crime of moral turpitude, including but not limited to embezzlement or fraud (iii) your material breach of the terms of this Agreement, or the confidentiality and intellectual property agreement between you and the Company (iv) your commission of any act of dishonesty, misconduct or fraud in any way impacting the Company, its clients, or its affiliates; (v) any misconduct by you which brings the Company into disrepute, including conduct that injures or impairs the Company’s business prospects, reputation or standing in the community; or (vi) your violation of written Company policies, including, without limitation, any violation of the Company’s Code of Conduct and Global Workforce Inclusion Policies; provided, however, that the Company shall allow you a reasonable opportunity (but not in excess of 10 calendar days) to cure, to the reasonable satisfaction of the Company, any act or omission applicable to part (i), (iii), or (vi) above, if curable in the Company’s reasonable determination; provided, further, that it is understood that willful or grossly negligent acts or omissions will not be curable.

		
	b.
	Change in Control.  “Change in Control” means (i) any person or entity becoming the beneficial owner, directly or indirectly, of securities of the Company representing fifty (50%) percent of the total voting power of all its then outstanding voting securities, (ii) a merger or consolidation of the Company in which its voting securities immediately prior to the merger or consolidation do not represent, or are not converted into securities that represent, a majority of the voting power of all voting securities of the surviving entity immediately after the merger or consolidation, (iii) a sale of substantially all of the assets of the Company or a liquidation or dissolution of the Company, or (iv) individuals who, as of this Agreement, constitute the Board of Directors (this body, the “Board,” and these members constituting, the “Incumbent Board”) cease for any reason to constitute at least a majority of such Board; provided that any individual who becomes a director of the Company subsequent to the date of this Agreement, whose election, or nomination for election by the Company stockholders, was approved by the vote of at least a majority of the directors then in office shall be deemed 

3
        

a member of the Incumbent Board; provided that, in each cases (i)‐(iv) of this definition, a transaction or series of transactions shall only constitute a Change in Control if it also satisfies the requirements of a change in control under U.S. Treasury Regulation 1.409A‐3(i)(5)(v), 1.409A‐3(i)(5)(vi), or 1.409A‐3(i)(5)(vii) under Section 409A of the Internal Revenue Code of 1954, as amended (the “Code”).  
		
	7.
	Parachute Payments.  In the event that the severance and other benefits provided for in this Agreement or otherwise payable to you (i) constitute “parachute payments” within the meaning of Section 280G of the Code and (ii) but for this Section 7, would be subject to the excise tax imposed by Section 4999 of the Code, then, at your discretion, your severance and other benefits under this Agreement shall be payable either (i) in full, or (ii) as to such lesser amount which would result in no portion of such severance and other benefits being subject to the excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the receipt by you on an after‐tax basis, of the greatest amount of severance benefits under this Agreement, notwithstanding  that all or some portion of such severance benefits may be taxable under Section 4999 of the Code.  

		
	8.
	Section 409A. To the extent (i) any payments to which you become entitled under this Agreement, or any agreement or plan referenced herein, in connection with your termination of service as Interim CEO with the Company constitute deferred compensation subject to Section 409A of the Code and (ii) you are deemed at the time of such termination of service as Interim CEO to be a “specified” employee under Section 409A of the Code, then such payment or payments shall not be made or commence until the earlier of (i) the expiration of the six (6)‐month period measured from the date of your “separation from service” (as such term is at the time defined in regulations under Section 409A of the Code) with the Company; or (ii) the date of your death following such separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax treatment to you, including (without limitation) the additional twenty percent (20%) tax for which you would otherwise be liable under Section 409A(a)(1)(B) of the Code in the absence of such deferral.  Upon the expiration of the applicable deferral period, any payments which would have otherwise been made during that period (whether in a single sum or in installments) in the absence of this paragraph shall be paid to you or your beneficiary in one lump sum (without interest). 

Except as otherwise expressly provided herein, to the extent any expense reimbursement or the provision of any in‐kind benefit under this Agreement (or otherwise referenced herein) is determined to be subject to (and not exempt from) Section 409A of the Code, the amount of any such expenses eligible for reimbursement, or the provision of any in‐kind benefit, in one calendar year shall not affect the expenses eligible for reimbursement or in kind benefits to be provided in any other calendar year, in no event shall any expenses be reimbursed after the last day of the calendar year following the calendar year in which you incurred such expenses, and in no event shall any right to reimbursement or the provision of any in‐kind benefit be subject to liquidation or exchange for another benefit.  

4
        

Payments pursuant to this Agreement (or referenced in this Agreement), and each installment thereof, are intended to constitute separate payments for purposes of Section 1.409A‐2(b)(2) of the regulations under Section 409A of the Code.
		
	9.
	At Will Employment.  Your service with the Company as Interim CEO is for no specific period of time.  Your service with the Company will be “at will,” meaning that either you or the Company may terminate your service as Interim CEO at any time and for any reason, with or without cause.  Any contrary representations that may have been made to you are superseded by this Agreement.  This is the full and complete agreement between you and the Company on this term.  Although your compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at will” nature of your service as Interim CEO may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you).

		
	10.
	Confidential Information and Other Company Policies.  You will be bound by and comply fully with the Company’s standard confidentiality agreement (a form of which was been provided to you), insider trading policy, code of conduct, and any other policies and programs adopted by the Company regulating the behavior of its employees, as such policies and programs may be amended from time to time to the extent the same are not inconsistent with this Agreement, unless you consent to the same at the time of such amendment.  

		
	11.
	Company Records and Confidential Information.

		
	a.
	Records.  All records, files, documents and the like, or abstracts, summaries or copies thereof, relating to the business of the Company or the business of any subsidiary or affiliated companies, which the Company or you prepare or use or come into contact with, will remain the sole property of the Company or the affiliated or subsidiary company, as the case may be, and will be promptly returned upon termination of your service as Interim CEO, subject to your reasonable needs to fulfill your fiduciary duties as a member of the Board of Directors.    

		
	b.
	Confidentiality.  You acknowledge that you have acquired and will acquire knowledge regarding confidential, proprietary and/or trade secret information in the course of performing your responsibilities for the Company, and you further acknowledge that such knowledge and information is the sole and exclusive property of the Company.  You recognize that disclosure of such knowledge and information, or use of such knowledge and information, to or by a competitor could cause serious and irreparable harm to the Company.    

		
	12.
	Indemnification.  You will continue to be named as an insured on the director and officer liability insurance policy currently maintained by the Company, or as may be maintained by the Company from time to time, and will continue to be subject to indemnification as required by the Company’s Bylaws and the Indemnification Agreement between you and the Company.  

		
	13.
	Arbitration.  You and the Company agree to submit to mandatory binding arbitration, in Santa Clara County, California, before a single neutral arbitrator, any and all claims arising out of or related to 

5
        

this Agreement and your service as Interim CEO with the Company and the termination thereof, except that each party may, at its or his option, seek injunctive relief in court related to the improper use, disclosure or misappropriation of a party’s proprietary, confidential or trade secret information.  YOU AND THE COMPANY HEREBY WAIVE ANY RIGHTS TO TRIAL BY JURY IN REGARD TO SUCH CLAIMS.  This agreement to arbitrate does not restrict your right to file administrative claims you may bring before any government agency where, as a matter of law, the parties may not restrict your ability to file such claims (including, but not limited to, the National Labor Relations Board, the Equal Employment Opportunity Commission and the Department of Labor).  However, you and the Company agree that, to the fullest extent permitted by law, arbitration shall be the exclusive remedy for the subject matter of such administrative claims.  The arbitration shall be conducted through the American Arbitration Association (the “AAA”), provided that, the arbitrator shall have no authority to make any ruling or judgment that would confer any rights with respect to the trade secrets, confidential and proprietary information or other intellectual property of the Company upon you or any third party.  The arbitrator shall issue a written decision that contains the essential findings and conclusions on which the decision is based.  The arbitration will be conducted in accordance with the AAA employment arbitration rules then in effect.  The AAA rules may be found and reviewed at http://www.adr.org.  If you are unable to access these rules, please let me know and I will provide you with a hardcopy.  The parties acknowledge that they are hereby waiving any rights to trial by jury in any action, proceeding or counterclaim brought by either of the parties against the other in connection with any matter whatsoever arising out of or in any way connected with this Agreement.  
		
	14.
	Compensation Recoupment. All amounts payable to you hereunder shall be subject to recoupment pursuant to the Company’s current compensation recoupment policy (as may be adopted during the Interim CEO Service Period), and any additional compensation recoupment policy or amendments to the then‐current policy adopted by the Board as required by law during the term of your service as Interim CEO with the Company that is applicable generally to executive officers of the Company.

		
	15.
	Director Compensation.  While the compensation you receive for your service as Interim CEO during the Interim CEO Service Period will be offset by your compensation received in your capacity as a member of the Board as set forth in Section 3(a) above, for the avoidance of doubt you will receive compensation under the Board’s compensation policies for non‐employee directors during and following the Interim CEO Service Period; it being understood that you will not be serving on any Board committees requiring director independence during the Interim CEO Service Period (though it is anticipated that you will return to service on such committees following such time).

		
	16.
	Miscellaneous.

		
	a.
	Successors.  This Agreement is binding on and may be enforced by the Company and its successors and permitted assigns and is binding on and may be enforced by you and your heirs and legal representatives.  Any successor to the Company or substantially all of its business (whether by purchase, merger, consolidation or otherwise) will in advance assume 

6
        

in writing and be bound by all of the Company’s obligations under this Agreement and shall be the only permitted assignee.
		
	b.
	Notices.  Notices under this Agreement must be in writing and will be deemed to have been given when personally delivered or two days after mailed by U.S. registered or certified mail, return receipt requested and postage prepaid.  Mailed notices to you will be addressed to you at the home address which you have most recently communicated to the Company in writing.  Notices to the Company will be addressed to the Chairman of the Board at the Company’s corporate headquarters.

		
	c.
	Waiver.  No provision of this Agreement will be modified or waived except in writing signed by you and an officer of the Company duly authorized by its Board.  No waiver by either party of any breach of this Agreement by the other party will be considered a waiver of any other breach of this Agreement.

		
	d.
	Severability.  In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision.

		
	e.
	Withholding. All sums payable to you hereunder shall be reduced by all federal, state, local and other withholding and similar taxes and payments required by applicable law.

		
	f.
	Entire Agreement.  This Agreement represents the entire agreement between the parties concerning the subject matter herein.  It may be amended, or any of its provisions waived, only by a written document executed by both parties in the case of an amendment, or by the party against whom the waiver is asserted.

		
	g.
	Governing Law.  This Agreement will be governed by the laws of the State of California without reference to conflict of laws provisions.

		
	h.
	Survival.  The provisions of this Agreement shall survive the termination of your service as Interim CEO for any reason to the extent necessary to enable the parties to enforce their respective rights under this Agreement.

[SIGNATURE PAGE TO AGREEMENT FOLLOWS]

7
        

Please sign and date this Agreement, and return it to me if you wish to accept service as Interim CEO at the Company under the terms described above.  
Best regards,

/s/ Michael Stankey    
Chairman of the Compensation Committee of the Board of Directors
Cloudera, Inc.

I, the undersigned, hereby accept and agree to the terms and conditions of my service as Interim CEO with the Company as set forth in this Agreement.

By: /s/ Martin Cole    
Martin I. Cole
Date: July 31, 2019    

[SIGNATURE PAGE TO INTERIM CEO LETTER AGREEMENT]Exhibit 10.1

 

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT AGREEMENT,
is made as of the Start Date (as defined below), by and between BIONIK LABORATORIES CORP., a Delaware corporation (hereinafter
referred to as the “Company”), and Loren Wass (hereinafter referred to as the “Employee”).

 

RECITALS

 

WHEREAS, the Company,
directly or through its subsidiaries, is engaged in the business of medical device research, development and production; and

 

WHEREAS, the Company
and the Employee have agreed to enter into an employment relationship upon the terms and subject to the conditions hereinafter
set forth.

 

NOW THEREFORE, in consideration
of the mutual covenants and promises herein contained and other good and valuable consideration, the parties agree as follows:

 

ARTICLE
1- EMPLOYMENT AND DUTIES

 

1.1       Appointment.
Subject to the terms and conditions of this Agreement, the Company hereby agrees to employ the employee, and the Employee hereby
accepts employment, in the position of Chief Commercialization Officer of the Company (the “Position”), effective on
the first day of employment with the Company, expected to be September 3rd, 2019, unless otherwise mutually agreed between
the Company and the Employee (the “Start Date”); provided that this Agreement shall not be binding on the Company until
the Employee gives official notice of resignation to his previous employer and informs the Company of such resignation and the
proposed Start Date.

 

1.2       Term.
The Employee shall be employed until terminated pursuant to the termination provisions set out in Article 4 and Article 5 of this
Agreement and to any amendments as may from time to time be agreed to in writing by the Employee and the Company (the “Term”).

 

1.3       Reporting
and Duties. The Employee shall report to the Chief Executive Officer of the Company. The Employee shall be responsible for (a)
the preparation and implementation of the global marketing and commercialization strategy for the Company and each of the Company’s
products already in market and those planned products under development, which includes go to market strategy and reimbursement
strategy for each geography, (b) delivering commercial sales in accordance with the Company’s budget, (c) support any and
all partnering efforts associated with the Company’s existing and planned products and (d) perform all of the normal and
customary duties, responsibilities and authorities customarily accorded to, and expected of the Position, including those duties,
responsibilities and authorities as may be reasonably designated by the Chief Executive Officer of the Company or the Board from
time to time (collectively, the “Duties”). Services performed pursuant to this Agreement shall be performed at the
Company’s U.S. headquarters in Boston, Massachusetts, or such place(s) as shall be mutually agreeable to the Company and
Employee. The Employee understands and agrees that the Position requires travel to the Company’s chief executive offices
in Toronto, Canada from time to time, as well as other destinations, to fulfill the Duties (expected travel 50% of the time). The
Employee agrees to comply with all applicable policies and rules of Company.

 

     

     

    

 

During the Term, the Employee shall faithfully
and honestly serve the Company and devote no less than full-time service to the business and affairs of the Company or, where applicable,
any subsidiary or other affiliate of the Company (individually a “Subsidiary” and collectively, the “Subsidiaries”),
including the Employee’s role in the Position and the Duties. The Employee shall use his best efforts to promote the interests
of the Company and its Subsidiaries. Notwithstanding the foregoing or anything else to the contrary herein, nothing in this Agreement
shall preclude the Employee from:

 

(a)       engaging
in charitable, education, communal or recreational activities; or

 

(b)       engaging
in another business enterprise as a passive investor; provided that in no event shall the Employee own more than 4.9% of any other
business enterprise and further provided that no such business enterprise shall be a competitor of the Company or its Subsidiaries.

 

However, the engagements described in 1.3(a)
– (b) above shall only be permissible so long as they do not result in a contravention of Article 3 hereof, or impair the
ability of the Employee to discharge his duties to the Company hereunder.

 

In addition, the Employee shall truly and
faithfully account for and deliver to the Company and its Subsidiaries, all money, securities and things of value belonging to
the Company or the Subsidiaries which the Employee may from time to time receive for, from or on account of the Company or the
Subsidiaries.

 

ARTICLE
2 - COMPENSATION

 

2.1       Base
Salary. The Employee will receive an annual base salary of Two Hundred Fifty Thousand Dollars ($250,000 USD), payable in accordance
with the Company’s standard payroll practices in effect from time to time, and subject to applicable statutory deductions
and withholding required by law (“Base Salary”). The Employee’s Base Salary will be reviewed on an annual basis
to determine potential increases, if any, based on the Employee’s performance and that of the Company.

 

2.2       Incentive
Compensation. The Employee will be entitled to participate in the Company’s 2014 Equity Incentive Plan or such other incentive
plan or arrangement adopted by the Company and applicable to Employee (the “Plan”) based on the terms of the Plan.
Subject to the immediately following sentence, the Employee shall be granted options to purchase an aggregate of 5,000 shares of
the Company’s common stock, at an exercise price per share equal to the fair market value of the Company’s common stock
on the date of grant, and which shall vest equally over a three (3) year period, with the first 1/3 vesting to occur on the one
(1) year anniversary of the Start Date. The granting of any options or other equity compensation is conditional on the written
approval of the Board, and subject to any applicable stockholder approval, and the Company reserves the right to alter, amend,
replace or discontinue the Plan or any other plan at any time, with or without notice to the Employee.

 

     

     

    

 

2.3       Bonus.
The Employee may be entitled to earn an annual bonus of up to 40% of Base Salary, payable based on the Employee’s and the
Company’s performance in the previous fiscal year (“Bonus”). The Bonus will be determined based on the achievement
of the Employee’s objectives that will be agreed to with the CEO for each particular fiscal year (the “Achievements”),
and shall be paid to Employee within the earlier of 90 days after the close of each fiscal year and the completion of the company
audit. The Employee must be employed for the entire fiscal year to be eligible for a Bonus for that year. Notwithstanding anything
herein to the contrary, the Company may extend the payment date for the Bonus for up to 60 days, if the Company in its discretion
determines it to be in the Company’s best interests to do so. The Achievements for the partial fiscal year ending March 31,
2020 shall be determined in good faith and agreed to in writing by the Employee and the Company within 14 days after the date of
this Agreement, and shall be pro rata based on the Start Date.

 

2.4       Benefits.
The Employee shall be entitled to participate in all of the Company’s (or applicable Subsidiary’s) benefit plans generally
available to its employees from time to time in accordance with the terms thereof. The Employee’s participation in such plans
shall become fully effective as of the commencement of his employment hereunder pursuant to the terms of such plans. The Company
reserves the right to alter, amend, replace or discontinue the benefit plans it makes available to its employees at any time, with
or without notice.

 

2.5       Vacation.
The Employee shall be entitled to four (4) weeks of paid vacation per calendar year. Such vacation shall be taken at a time or
times acceptable to the Company. The Employee shall be allowed to carry forward any unused vacation into the next calendar year
for up to one (1) month.

 

2.6       Expense
Reimbursement. The Employee shall be reimbursed for all reasonable expenses actually and properly incurred by him in connection
with the performance of his duties hereunder. The Employee shall submit to the Company written, itemized expense accounts, together
with supporting invoices, acceptable to the Company and such other additional substantiation and justification as the Company may
reasonably request within sixty (60) days after the expenses have been incurred.

 

ARTICLE
3- COVENANTS

 

3.1       No
Restrictions on Employee’s Employment. The Employee acknowledges and affirms that he is not a party to any agreement or understanding
that would conflict or interfere with, or prevent or limit him from being employed by or perform services for the Company.

 

3.2       Confidential
Information. The Employee hereby acknowledges that, by reason of his employment with the Company, he has and will acquire information
about matters and things which are confidential to the Company and/or the Subsidiaries (the “Confidential Information”),
and which Confidential Information is the exclusive property of the Company and/or the Subsidiaries, respectively. The Confidential
Information includes, without limitation, information concerning the Company’s and the Subsidiaries’ strategic plans,
product research and development plans, details and results, trade secrets, supplier lists, data, work product developed by or
for the Company or the Subsidiaries, and all other data and information concerning the business and affairs of the Company and
the Subsidiaries. Notwithstanding anything to the contrary contained herein, for the purposes hereof, Confidential Information
shall not include:

 

     

     

    

 

(a)       information
that is generally available to and known by the public at the time of disclosure to the Employee, provided that such disclosure
is through no direct or indirect fault of the Employee or person(s) acting on the Employee's behalf; or

 

(b)       information
which the Employee is required to disclose pursuant to applicable law, policies or due processes of applicable regulatory bodies
or legal or regulatory proceedings; provided that the Employee provides the Company with prompt notice of same and assists the
Company in seeking to prevent or limit such requirement.

 

The Employee agrees that during the Term
and at all times thereafter, he shall not for any reason (except in the performance of his responsibilities for the Company) directly
or indirectly, (i) use for his own benefit or for the benefit of others, (ii) disseminate, publish or disclose, or (iii) authorize
or permit the use, dissemination or disclosure by any person, firm or entity, any Confidential Information without the express
written consent of the Board. Upon termination of the Employee’s employment or this Agreement, or at any time at the request
of the Company for any reason, the Employee agrees to return to the Company (or, in the case of electronic items, permanently delete)
all documents, records, storage, data, samples, and other property of the Company and its Subsidiaries, together with all copies
thereof which contain or incorporate any Confidential Information.

 

Under the federal Defend Trade Secrets
Act of 2016, the Employee shall not be held criminally or civilly liable under and federal or state trade secret law for the disclosure
of a trade secret that:  (a) is made (i) in confidence to a federal, state, or local government official, either directly
or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or
(b) is made to the Employee’s attorney in relation to a lawsuit for retaliation against the Employee for reporting a suspected
violation of law; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made
under seal.

 

3.3       Intellectual
Property, Inventions and Patents. As part of the consideration for this Agreement and for his employment by the Company, subject
to the provisions of this Agreement, the Employee hereby assigns to the Company, as and when same arise, his entire right, title
and interest, including all intellectual property rights and trade secret rights, in and to any and all work product that is conceived,
created, developed or otherwise generated by the Employee from time to time that relates to the business of the Company or the
Subsidiaries, including but not limited to all inventions, research, designs, trade secrets, improvements, plans, specifications
and documentation (collectively, “Work Product”), all of which shall be deemed a work for hire for the Company under
the U.S. Copyright Act to the fullest extent permitted under the law. The Employee further agrees that he will promptly, fully
disclose to the Company all such Work Product and will, at any time from the date hereof, including during and after his employment
with the Company, at the Company’s expense, render to the Company or the Subsidiaries such cooperation and assistance as
the Company or the Subsidiaries may deem advisable in order to obtain copyright, patent, trademark or industrial design registrations
as the case may be on, or otherwise vest, perfect or defend the Company’s or the Subsidiaries’ rights with respect
to, any or all Work Product. Such cooperation and assistance shall include, but is not limited to, the execution of any and all
applications for copyright, patent, trademark or industrial design registrations, assignments of copyrights and other instruments
in writing which the Company and the Subsidiaries may deem necessary or desirable. The Employee hereby irrevocably waives all of
his moral rights in the Work Product in favor of the Company and its Subsidiaries and their respective successors, assignees and
licensees.

 

     

     

    

 

The Employee shall take all precautions
to maintain and protect the legal rights of the Company and its Subsidiaries in the Work Product, and to maintain the confidentiality
of trade secrets included in the Work Product in accordance with Section 3.1 hereof. For certainty, no license to the Work Product
is granted to the Employee, except to the extent required for the performance of his responsibilities under this Agreement.

 

The Employee irrevocably appoints any other
officer of the Company or the Subsidiaries from time to time to be his attorney, with full power of substitution, to do on the
behalf of the Employee anything that the Employee can lawfully do by an attorney to do all acts and things in relation to ownership
of the Work Product which the Company or the Subsidiaries shall deem desirable, and to do, sign and execute all documents, conveyances,
deeds, assignments, transfers, assurances and other instruments which may reasonably be necessary or desirable for the purpose
of registering, vesting, perfecting; defending, assigning or otherwise dealing with the Work Product. Such power of attorney is
given for valuable consideration acknowledged by the Employee to be coupled with an interest, shall not be revoked by the bankruptcy
or insolvency of the Company or the Subsidiaries, and may be exercised by the officers of any successor or assign of the Company
or the Subsidiaries.

 

The Employee hereby covenants that the
Work Product will not violate or infringe any intellectual property rights of any third party or constitute an unauthorized use
of confidential or proprietary information of any third party.

 

All of the aforesaid covenants in this
Section shall be binding on the assigns, executors, administrators and other legal representatives of the Employee.

 

3.4       Non-Solicitation
of Employees. The Employee shall not, during the period from the date hereof to that date which is one (1) year following the termination
of this Agreement or the Employee’s employment, for any reason, directly or indirectly, hire any employees or consultants
of the Company or Subsidiaries, or induce or attempt to induce, solicit or attempt to solicit, any of the employees or consultants
of the Company or Subsidiaries to leave their employment or engagement with the Company.

 

3.5       Non-Solicitation
of Customers and Suppliers. The Employee shall not, during the period from the date hereof to that date which is one (1) year following
the termination of this Agreement or the termination of the Employee’s employment, for any reason, directly or indirectly,
without the prior written consent of the Company, solicit or attempt to solicit any customers of the Company or the Subsidiaries
with whom the Employee had contact or material knowledge of, for the purpose of selling to those customers any products or services
which are the same as or substantially similar to or in any way competitive with the products or services sold by the Company or
the Subsidiaries at the time of termination of this Agreement. The Employee shall not, during the period from the date hereof to
that date which is one (1) year following the termination of this Agreement or the termination of the Employee’s employment,
for any reason, directly or indirectly, without the prior written consent of the Company, solicit or attempt to solicit any suppliers
of the Company or the Subsidiaries with whom the Employee had contact with or material knowledge of, for the purpose of diverting
or attempting to divert business away from the Company or the Subsidiaries.

 

     

     

    

 

3.6       Non-Competition.
The Employee shall not, at any time during the period from the date hereof to that date which is one (1) year following the date
of termination of this Agreement or the Employee’s employment, engage in the commercialization of medical devices similar
to those, or devices that are in any way competitive with the products or services, developed, being developed, commercialized
and/or sold by the Company or the Subsidiaries during the term of this Agreement and at the time of the termination of this Agreement
(“Competitive Activity”). The Employee may not engage in such Competitive Activity either individually or in partnership
or jointly or in conjunction with any person as principal, agent, employee, consultant, shareholder (other than a holding of shares
listed on a United States stock exchange that does not exceed five percent (5%) of the outstanding shares so listed) or in any
other manner whatsoever, nor shall the Employee lend money to, guarantee the debts or obligations of or permit his name or any
part thereof to be used or employed by any person engaged in a similar business to the Company or the Subsidiaries. The Company
shall have the option to elect whether to enforce this Section 3.6. If the Company elects to enforce this Section 3.6, it shall
continue to pay the Employee’s base salary (at the rate at which it was paying the Employee’s base salary on the date
of termination) for as long as it wishes to enforce this Section 3.6, up to one (1) year following termination of employment. The
Company’s payment obligation pursuant to this Section 3.6 shall apply regardless of the circumstances or reasons leading
to the termination of the Employee’s employment. If the Company fails to continue the Employee’s base salary pursuant
to the terms of this Section 3.6, the Employee’s restrictions set forth in this Section 3.6 shall be void thereafter.

 

3.7       Disparaging
Comments. The Employee agrees not to make critical, negative or disparaging remarks about the Company or its management, business
or employment practices; provided that nothing in this paragraph shall be deemed to prevent the Employee from responding fully
and accurately to any question, inquiry or request for information when required by applicable law or legal process, or to enforce
this Agreement. The Company agrees to direct its officers and directors not to make critical, negative or disparaging remarks about
the Employee; provided that nothing in this paragraph shall be deemed to prevent the Company or its officers or directors from
responding fully and accurately to any question, inquiry or request for information when required by applicable law or legal process,
or to enforce this Agreement.

 

3.8       Acknowledgement,
Waiver and Enforcement. The Employee confirms that the restrictions contained in this Article 3 are reasonable and valid to protect
the legitimate business interests of the Company and the Subsidiaries, including its business plans and marketing and commercialization
strategies. The Employee hereby agrees and acknowledges that compliance with the Covenants set forth in this Agreement are necessary
to protect the business and goodwill of the Company, that it would be extremely difficult to measure the damages that might result
from any breach of any of the covenants of the Employee contained herein, and that any breach of any of the covenants of the Employee
might result in irreparable injury to the business for which monetary damages could not adequately compensate. If a breach of any
of the covenants of the Employee occurs, the Company shall be entitled, in addition to any other rights or remedies the Company
may have at law or in equity, (i) to have injunctions (both preliminary and permanent) issued by any competent court (without the
need to post a bond) enjoining and restricting the Employee and all other parties involved therein from continuing such breach,
and (ii) to recovery of all reasonable sums and costs, including attorneys’ fees, incurred by the Company to enforce these
provisions.

 

     

     

    

 

3.9       Notwithstanding
anything to the contrary herein, if any applicable law or governmental entity shall reduce the time period or scope during which
the Employee shall be prohibited from engaging in any competitive or soliciting activity described in this Article 3, the period
of time or scope, as the case may be, for which the Employee shall be prohibited shall be reduced to the maximum time or scope
permitted by law.

 

3.10     Survival
and Enforceability. It is expressly agreed by the parties hereto that the provisions of this Article 3 shall survive the termination
of this Agreement and the Employee’s employment.

 

ARTICLE
4 – DEATH; DISABILITY

 

4.1       Death.
If the Employee dies while employed under this Agreement, this Agreement shall terminate immediately and the Company shall pay
to the Employee’s estate, any earned Base Salary, accrued vacation, if any, that is unpaid up to the date of his death.

 

4.2       Termination
by Disability. The Company may terminate this Agreement as a result of any mental or physical disability or illness which results
in (a) the Employee being unable to substantially perform his duties for a continuous period of 150 days or for periods aggregating
180 days within any period of 365 days or (b) the Employee being subject to a permanent or indefinite inability to perform essential
functions based on the opinion of a qualified medical provider chosen by the Company. Termination will be effective on the date
designated by the Company, and the Employee will be paid his annual Base Salary, accrued vacation, if any, and benefits as set
out in Section 2.4 through the date of termination.

 

ARTICLE
5 - TERMINATION OF EMPLOYMENT

 

5.1       Termination
by Company for Cause. The Company may terminate this Agreement for cause at any time without any prior notice. The Employee will
be provided with any unpaid, earned Base Salary incurred up to the date of termination. For the purposes of this Agreement, “cause”
shall mean any of:

 

(a)       a
material breach by the Employee of the terms of this Agreement;

 

(b)       a
conviction of or plea of guilty or nolo contendere to any felony or any other crime involving dishonesty or moral turpitude;

 

(c)       the
commission of any act of fraud or dishonesty, or theft of or intentional damage to the property of the Company;

 

(d)       willful
or intentional breach of the Employee’s fiduciary duties to the Company;

 

     

     

    

 

(e)       the
violation of a material policy of the Company as in effect from time to time; or

 

(f)       any
act or conduct that would constitute cause at common law.

 

5.2       Termination
by Company for Other than Cause. The Company may terminate this Agreement and the Employee’s employment, for any reason without
cause and provided that the Employee executes a general release to be provided to the Company in form and substance acceptable
to the Company, the Company shall pay to the Employee an amount equal to two (2) months’ base salary in accordance with the
Company’s normal payroll schedule plus accrued unused vacation, if any.

 

5.3       Termination
by Employee. The Employee may terminate this Agreement and his employment at any time, for any reason, provided that the Employee
provides the Company with thirty (30) days’ prior written notice. The Employee agrees to use his best effort to assist the
Company to complete an effective reallocation of his responsibilities upon the giving of such notice. In case of Good Reason (as
defined below), the Company shall pay to the Employee: (i) the Severance; and (ii) accrued vacation time if any; provided that
the Company shall not be required to pay the Severance in the event the Company elects to enforce Section 3.6, and continues paying
Employee’s salary pursuant to Section 3.6 in an amount no less than the Severance amount. For purposes of this Employment
Agreement, “Good Reason” shall mean any of:

 

		(1)	A material diminution in the Employee's base compensation;

 

		(2)	A material diminution in the Employee's authority, duties, or responsibilities; or

 

		(3)	Any other action or inaction that constitutes a material breach by the Company of this Employment
Agreement.

 

For Good Reason to exist, the Employee
must provide notice to the Company of the existence of any of the foregoing conditions within ninety (90) days of the initial existence
of the condition, and the Company shall upon such notice have a period of forty-five (45) days during which it may remedy the condition
(and upon such remedy Good Reason shall be deemed not to have existed).

 

5.4       Limitation
of Liability. The Employee acknowledges, understands and agrees that the payments and other benefits provided for in this Article
5 represent the Company’s maximum termination and severance obligations to the Employee. No other notice or severance entitlements
shall apply. This provision shall remain in full force and effect unamended, notwithstanding any other alterations to the terms
and conditions of the Employee’s employment, unless agreed to by the Company in writing. The Employee also acknowledges,
understands and agrees that any such payment by the Company to the Employee on termination of the Employee’s employment shall
not prevent the Company from alleging cause for the termination.

 

     

     

    

 

5.5       Effect
of Termination. Upon any termination of this Agreement, the Employee shall immediately deliver or cause to be delivered to the
Company all Confidential Information and Company property which are in the possession, charge, control or custody of the Employee.

 

ARTICLE
6 - GENERAL

 

6.1       Release.
Upon any termination of this Agreement or the Employee’s employment, the Employee agrees to release the Company, the Subsidiaries,
and all officers, directors and employees of the Company or the Subsidiaries from all actions, causes of action, claims or demands
as a result of such termination, except as otherwise expressly provided in this Agreement. Upon compliance with the applicable
termination provisions of this Agreement by the Company, the Employee agrees to deliver to the Company a full and final written
release of and from all actions or claims in connection with this Agreement and the Employee’s employment in favor of the
Company, the Subsidiaries, and their directors, officers and employees in a form to be provided by the Company.

 

6.2       Recitals.
The parties agree that the Recitals set out herein are true and accurate and shall form part of this Agreement.

 

6.3       Headings.
The division of this Agreement into articles and sections and the insertion of headings are for the convenience of reference only
and shall not affect the construction or interpretation of this Agreement.

 

6.4       Assignment.
This Agreement shall be personal as to the Employee and shall not be assignable by the Employee subject to the terms herein. This
Agreement shall inure to the benefit of and be binding upon the heirs, executors, administrators and legal personal representatives
of the Employee and the successors and assigns of the Company. The Company may assign this Agreement, in its sole discretion, to
any corporate affiliate or Subsidiary of the Company.

 

6.5       Entire
Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and cancels
and supersedes any prior understandings and agreements between the parties hereto with respect thereto, whether verbal or in writing.
There are no other written or verbal representations, warranties, terms, conditions, undertakings or collateral agreements, express,
implied or statutory between the parties.

 

6.6       Amendments.
No amendment to this Agreement shall be valid or binding unless set forth in writing and duly executed by both of the parties hereto.
The waiver by any party hereto of a breach of any provision of this Agreement shall not operate or be construed as a waiver of
any subsequent breach by any party.

 

6.7       Severability.
If any provision of this Agreement is determined to be invalid or unenforceable in whole or in part, such invalidity or unenforceability
shall attach only to such provision or part thereof and the remaining part of such provision and all other provisions hereof shall
continue in full force and effect.

 

6.8       Further
Acts. The parties shall do all such further acts and things and provide all such assurances and deliver all such documents in writing
as may be required, from time to time in order to fully carry out the terms, provisions and intent of this Agreement.

 

     

     

    

 

6.9       Notice.
Any demand, notice or other communication to be given in connection with this Agreement shall be given in writing by personal delivery,
electronic delivery or by registered mail addressed to the recipient as follows:

 

Bionik Laboratories Corp.

483 Bay Street, N105

Toronto, Ontario M5G 2C9

Telephone: (416) 640-7887

Email: ed@bioniklabs.com

 

Loren Wass

At the most recent address
on file with the Company

Email: lwwass@charter.net

 

or such other address or number as may
be designated by either party to the other in accordance herewith. Any notice given by personal delivery will be conclusively deemed
to have been given on the day of actual delivery of the notice and, if given by registered mail, on the third day, other than a
Saturday, Sunday or statutory holiday in Ontario, Canada or the Commonwealth of Massachusetts, following the deposit of the notice
in the mail. If the party giving any notice knows or ought reasonably to know of any difficulties with the postal system that might
affect the delivery of mail, any such notice may not be mailed but must be given by personal delivery. In the case of electronic
delivery, on the same day that it was sent if sent on a business day and the acknowledgement of receipt is received by the sender
before 5:00 p.m. (in the place of receipt) on such day, and otherwise on the first business day thereafter.

 

6.10     Jurisdiction.
This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts. Each of the
parties hereto agrees that any action or proceeding related to this Agreement must be brought in any court of competent jurisdiction
in the Commonwealth of Massachusetts, and for that purpose hereby submits to the jurisdiction of such Massachusetts court.

 

6.11     Section
409A. This Agreement is intended to comply with or be exempt from Section 409A of the Code and will be interpreted, administered
and operated in a manner consistent with that intent. Notwithstanding anything herein to the contrary, if at the time of the Employee’s
separation from service with the Company he is a “specified employee” as defined in Section 409A of the Code (and the
regulations thereunder) and any payments or benefits otherwise payable hereunder as a result of such separation from service are
subject to Section 409A of the Code, then the Company will defer the commencement of the payment of any such payments or benefits
hereunder (without any reduction in such payments or benefits ultimately paid or provided to the Employee) until the date that
is six months following the Employee’s separation from service with the Company (or the earliest date as is permitted under
Section 409A of the Code), and the Company will pay any such delayed amounts in a lump sum at such time. If any other payments
of money or other benefits due to the Employee hereunder could cause the application of an accelerated or additional tax under
Section 409A of the Code, such payments or other benefits shall be deferred if deferral will make such payment or other benefits
compliant under Section 409A of the Code, or otherwise such payment or other benefits shall be restructured, to the extent possible,
in a manner, determined by the Company, that does not cause such an accelerated or additional tax. To the extent any reimbursements
or in-kind benefits due to the Employee under this Agreement constitute “deferred compensation” under Section 409A
of the Code, any such reimbursements or in-kind benefits shall be paid to the Employee in a manner consistent with Treas. Reg.
Section 1.409A-3(i)(1)(iv). Each payment made under this Agreement shall be designated as a “separate payment” within
the meaning of Section 409A of the Code. References to “termination of employment” and similar terms used in this Agreement
are intended to refer to “separation from service” within the meaning of Section 409A of the Code to the extent necessary
to comply with Section 409A of the Code. Whenever a payment under this Agreement may be paid within a specified period, the actual
date of payment within the specified period shall be within the sole discretion of the Company. In no event may the Employee, directly
or indirectly, designate the calendar year of any payment to be made under this Agreement. Any provision in this Agreement providing
for any right of offset or set-off by the Company shall not permit any offset or set-off against payments of “non-qualified
deferred compensation” for purposes of Section 409A of the Code or other amounts or payments to the extent that such offset
or set-off would result in any violation of Section 409A or adverse tax consequences to the Employee under Section 409A.

 

     

     

    

 

6.12     Independent
Legal Advice. The Employee acknowledges that he has been advised to seek independent legal counsel in respect of the Agreement
and the matters contemplated herein, including but not limited to the Covenants in Article 3 hereof. To the extent that he declines
to receive independent legal counsel in respect of the Agreement, he waives the right, should a dispute later develop, to rely
on his lack of independent legal counsel to avoid his obligations, to seek indulgences from the Company or to otherwise attack
the integrity of the Agreement and the provisions thereof, in whole or in part.

 

[Remainder
of Page Intentionally Left Blank; Signature Page Follows]

 

     

     

    

 

IN WITNESS WHEREOF
this Agreement has been executed by the parties hereto as of the date first written above.

 

	 	BIONIK LABORATORIES CORP.	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Eric Dusseux	 
	 	Name:  	Eric Dusseux	 
	 	Title:  	CEO	 
	 	 	 	 
	 	 	 	 
	 	 	/s/ Loren Wass	 
	 	NAME: 	Loren Wass

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]